Aixindawei Pharmaceutical Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • PE Growth

  • Investors
  • 15

Aixindawei Pharmaceutical General Information

Description

Developer of small-molecule drug conjugates intended to treat advanced malignant solid neoplasms and hematological cancers. The company provides technology that utilizes aldo-keto reductase family 1 member C3 (AKR1C3) enzyme activation and hypoxia-activated prodrug platforms to develop targeted therapies, including AST-3424, AST-001, AST-002, AST-003, AST-004, and AST-007, enabling the oncology sector to access selective, intracellularly activated treatments for treatment-resistant tumors.

Contact Information

Formerly Known As
Guangzhou Aihenghao Pharmaceutical Technology, Shenzhen Aihenghao Pharmaceutical Technology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 12, Biomedical Innovation Industrial Park
  • Number 14 Jinhui Road, Pingshan District
  • Shenzhen, Guangdong
  • China
+86 0755
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • Building 12, Biomedical Innovation Industrial Park
  • Number 14 Jinhui Road, Pingshan District
  • Shenzhen, Guangdong
  • China
+86 0755

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aixindawei Pharmaceutical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. PE Growth/Expansion Completed Generating Revenue
10. Secondary Transaction - Private 07-May-2026 Completed Generating Revenue
9. Later Stage VC (Series C) 06-May-2026 Completed Generating Revenue
8. Secondary Transaction - Private 28-Mar-2023 Completed Generating Revenue
7. Later Stage VC (Series B1) 27-Mar-2023 Completed Generating Revenue
6. Later Stage VC (Series B) 15-Nov-2022 Completed Generating Revenue
5. Later Stage VC 09-Feb-2021 Completed Generating Revenue
4. Later Stage VC (Series A1) 06-Nov-2019 Completed Generating Revenue
3. Early Stage VC 08-Jul-2019 Completed Generating Revenue
2. Early Stage VC 23-Apr-2018 Completed Generating Revenue
To view Aixindawei Pharmaceutical’s complete valuation and funding history, request access »

Aixindawei Pharmaceutical Patents

Aixindawei Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026201124-A1 Method for treating cancer with ast-001 and use thereof in preparing medicament for treating cancer Pending 28-Mar-2025
WO-2026179849-A1 Ast-3424 metabolite and use Pending 25-Feb-2025
WO-2026166538-A1 Lyophilized preparation solution of ast-3424, lyophilized preparation, method, and use Pending 10-Feb-2025
WO-2026149530-A1 Treatment of cancer and tumor patients with mutations in fanc gene, xrcc gene, or atm gene Pending 09-Jan-2025
WO-2026145755-A1 Method for treating patients with drug tolerance by akr1c3 enzyme-activated compound Pending 03-Jan-2025
To view Aixindawei Pharmaceutical’s complete patent history, request access »

Aixindawei Pharmaceutical Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Fosun Health Capital Corporate Venture Capital Minority
Fosun Pharma Corporation Minority
Changna Investment Growth/Expansion Minority
Hunan Salt Industry Group Corporation Minority
China Capital Management PE/Buyout Minority
You’re viewing 5 of 15 investors. Get the full list »

Aixindawei Pharmaceutical FAQs

  • When was Aixindawei Pharmaceutical founded?

    Aixindawei Pharmaceutical was founded in 2014.

  • Where is Aixindawei Pharmaceutical headquartered?

    Aixindawei Pharmaceutical is headquartered in Shenzhen, China.

  • What industry is Aixindawei Pharmaceutical in?

    Aixindawei Pharmaceutical’s primary industry is Drug Discovery.

  • Is Aixindawei Pharmaceutical a private or public company?

    Aixindawei Pharmaceutical is a Private company.

  • What is Aixindawei Pharmaceutical’s current revenue?

    The current revenue for Aixindawei Pharmaceutical is .

  • How much funding has Aixindawei Pharmaceutical raised over time?

    Aixindawei Pharmaceutical has raised $32.3M.

  • Who are Aixindawei Pharmaceutical’s investors?

    Fosun Health Capital, Fosun Pharma, Changna Investment, Hunan Salt Industry Group, and China Capital Management are 5 of 15 investors who have invested in Aixindawei Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process